WASHINGTON – Swiss pharmaceutical maker Novartis AG will stop selling a drug to relieve constipation after it was linked to a higher chance of heart attack, stroke and worsening heart chest pain that ...

High-profile, quick-growing IBS drug shelved because of cardio risks. FDA has asked Novartis to pull Zelnorm (tegaserod) from the market five years after its approval, eliciting a swift and surprised ...

Novartis said Friday it has pulled its irritable bowel treatment Zelnorm (tegaserod maleate) off the US market after new clinical data showed an increased risk of cardiovascular events in patients ...

Novartis has notified the FDA that Zelnorm (tegaserod maleate) will no longer be available under a treatment investigational New Drug Application (T-IND) protocol to treat irritable bowel syndrome ...

Dear Dr. Gott: I love your column. It’s been very beneficial to my family in many ways. I took Zelnorm over a year ago, until my doctor said the Food and Drug Administration had taken it off the ...

ZURICH, May 31 (Reuters) - Swiss health authorities ordered on Thursday the withdrawal of Novartis's Zelmac, known as Zelnorm in the United States, for the treatment of irritable bowel syndrome.

The U.S. Food and Drug Administration has asked Novartis to stop selling its chronic constipation drug Zelnorm after combining 29 clinical studies turned up an increased cardiovascular risk. The ...

The FDA has agreed to permit limited use of Novartis’ Zelnorm (tegaserod maleate) by some patients through a restricted access program, following the drug’s voluntary withdrawal over cardiovascular ...

Novartis pulled bowel drug Zelnorm from U.S. shelves on Friday at the request of regulators because clinical trial data indicated a possible link to heart attacks and strokes. The move is a body blow ...

Novartis, the manufacturer of Zelnorm, has notified the FDA that they will no longer provide Zelnorm (tegaserod maleate) under a treatment investigational new drug application (T-IND) protocol to ...

Novartis ' Zelnorm, approved by U.S. regulators in July, could well reach annual sales of $1 billion or more. But in order for that to happen, Novartis has to convince gun-shy doctors that the drug is ...